Partnership with Becton Dickinson and development partnership for MANF's orphan indications could easily triple the .20 price target to .60 or higher.
Uplisting to national exchange will attract the funds and institutional investors.
Tremendous upside from here.
The bottom line with AMBS is that at the current share price that anyone who is aware of the company's tremendous potential and isn't buying a few shares to hold for a year or two is missing a great opportunity to make substantial profits.
That's just the way it is.
AMBS is under strong accumulation. The total short volume for the week was in the 45% range.
New and existing shareholders are pulling shares out of the float for a long term hold. The up trend in the share price will continue and I expect one p.r. will double the share price in a day and AMBS will be on its way to up listing to the NASDAQ before the end of the second quarter of 2014.
The J.P. Morgan Healthcare Conference and the T.B.I. presentation at the United Nations are just two of the catalysts that will result in additional exposure of the company to the media and to new shareholders. The penny flippers and the shorts will be chasing the share price going forward.
Follow the company on Twitter: @AmarantusBio
You'll soon regret not having bought more shares of AMBS. Maybe not today or tomorrow but soon and for the rest of your life.
Best opportunity for substantial profits in the market.
There are so many reason to own AMBS shares over the next year and beyond that it's difficult to comprehend why anyone is selling at such a low price.
p.s. It is appreciated.
The rocket is on the launching pad and the fuel is being added.
This is overdue for a run towards .20.
The investors must believe that there is substantial upside buying shares at $18.35 if they are investing $3 billion dollars.
They had to invest $3 billion to get that price. Currently you can buy one share for less than $18.35. I would believe that now is a great time to buy a few shares, I'm certain that the investors had better information than the market.
Zack's bio-tech analyst, Jason Napadano, has a buy rating on "AMBS".
The company's patented MANF drug could offer cures for numerous diseases.